KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

Fulgent Genetics (FLGT) Accumulated Depreciation & Amortization (2016 - 2025)

Fulgent Genetics' Accumulated Depreciation & Amortization history spans 10 years, with the latest figure at $57.9 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 12.06% year-over-year to $57.9 million; the TTM value through Dec 2025 reached $57.9 million, up 12.06%, while the annual FY2025 figure was $57.9 million, 12.06% up from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $57.9 million at Fulgent Genetics, up from $51.7 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $57.9 million in Q4 2025 and bottomed at $14.7 million in Q2 2021.
  • The 5-year median for Accumulated Depreciation & Amortization is $44.4 million (2022), against an average of $38.3 million.
  • The largest annual shift saw Accumulated Depreciation & Amortization surged 120.48% in 2022 before it grew 0.15% in 2024.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $19.6 million in 2021, then soared by 120.48% to $43.3 million in 2022, then increased by 19.3% to $51.6 million in 2023, then increased by 0.15% to $51.7 million in 2024, then grew by 12.06% to $57.9 million in 2025.
  • Per Business Quant, the three most recent readings for FLGT's Accumulated Depreciation & Amortization are $57.9 million (Q4 2025), $51.7 million (Q4 2024), and $45.4 million (Q2 2024).